Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pancreatic Cancer Treatment Benefit-Cost Analysis

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Oct 13, 2022 2:08pm

230 Views

Post# 35022944

RE:Pancreatic Cancer Treatment Benefit-Cost Analysis

Pretty good analysis actually. Doug Loe reports have 2030 revenue as Royalties at 6$ plus per share for Pancreatic, Breast and Myeloma. At 20x Earnings 20 x 6$ CDN that is a 2030 valuation of roughly $120 per share. I don't think it covers how many markets in the world that would cover? That's just a rough Earnings 2030 I've been using to try and come up with a share value Roche will offer. Roche has completed 103 Pancreatic Cancer trials so I think they know what they are doing and looking for. Crazy number 103 but maybe 104 ours " THE ONE" Cheers!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals